ReviewMelanoma management2014
No one should die of melanoma: a vision or impossible mission?
Review in Melanoma management, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
- Evaluation of the Contribution of Repeat Total Body Photography for the Early Diagnosis of Melanoma.Dermatology (Basel, Switzerland) · 2026Article
- A nomogram for predicting survival in patients with nodular melanoma: A population-based study.Medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While the incidence of early-stage melanoma has dramatically increased over the past decades, the incidence and mortality rates of thick melanomas have remained relatively stable during the same period. A number of alternative theories have been postulated in order to explain these divergent trends between thin and thick melanomas, among which is the question of whether nodular melanoma may originate in the dermis. This concept has gained support from recent improvements in the understanding of the origin of melanocytes and the morphological and molecular diversity of melanoma. A dermal origin would plausibly explain why efforts at improving the early detection of melanoma largely fail, as it implies an initially intradermal growth that is hidden from our eyes until clinical signs and symptoms become only secondarily apparent. In light of this, at the current stage, the vision that no one should die of melanoma is an impossible mission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.